Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons (vol 9, pg 1491, 2018)

被引：1
|
作者：
Balijepalli, Chakrapani [1 ]
Shirali, Rohan [1 ]
Kandaswamy, Prashanth [2 ]
Ustyugova, Anastasia [2 ]
Pfarr, Egon [2 ]
Lund, Soren S. [2 ]
Druyts, Eric [1 ]
机构：
[1] Precis Hlth Econ, Vancouver, BC, Canada
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
DIABETES THERAPY | 2019年 / 10卷 / 01期
关键词：
D O I：
10.1007/s13300-018-0543-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The authors have updated Fig. 3 which was incorrectly published in the original publication.
引用
收藏
页码：325 / 326
页数：2
相关论文
共 50 条
  • [21] Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes
    Hamrick, Irene
    Goblirsch, Matthew Joseph
    Tuan, Wen-Jan
    Beckham, Felicia
    GERIATRIC NURSING, 2022, 46 : 86 - 89
  • [22] Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
    Koska, Juraj
    Sands, Michelle
    Burciu, Camelia
    Reaven, Peter
    DIABETES & VASCULAR DISEASE RESEARCH, 2015, 12 (03): : 154 - 163
  • [23] Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
    Deacon, C. F.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 7 - 18
  • [24] Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis
    Overbeek, Jetty A.
    Bakker, Marina
    van der Heijden, Amber A. W. A.
    van Herk-Sukel, Myrthe P. P.
    Herings, Ron M. C.
    Nijpels, Giel
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34 (05)
  • [25] Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
    Liu, Dan
    Jin, Biao
    Chen, Wei
    Yun, Peng
    BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (1):
  • [26] Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
    Dan Liu
    Biao Jin
    Wei Chen
    Peng Yun
    BMC Pharmacology and Toxicology, 20
  • [27] A pharmacoeconomic evaluation for diabetes type 2 (DM 2) patients with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy
    Fon, F.
    Celaya, J. M.
    Ayala, C.
    Antunez, O.
    Garcia-Contreras, F.
    VALUE IN HEALTH, 2007, 10 (06) : A254 - A254
  • [28] Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
    Cox, Mary Elizabeth
    Rowell, Jennifer
    Corsino, Leonor
    Green, Jennifer B.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2010, 2 : 7 - 19
  • [29] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
    Deacon, Carolyn F.
    Holst, Jens J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2047 - 2058
  • [30] SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Lizan, L.
    Aceituno, S.
    Franch, J.
    Perez, A.
    Granell, M.
    Fuster, E.
    VALUE IN HEALTH, 2014, 17 (07) : A348 - A348
12345